This summary provides an overview of key findings from studies presented at the 2007 Gastrointestinal Cancers Symposium on treatments for pancreatic cancer: 1) A phase III trial found that adding bevacizumab to gemcitabine did not improve survival for advanced pancreatic cancer. 2) A phase II study showed promising results for cetuximab plus gemcitabine/oxaliplatin, with a high response rate and tolerable toxicity. 3) Population-based analyses found adjuvant radiotherapy after surgery and chemo-radiotherapy improved survival outcomes for pancreatic cancer.